Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a human growth hormone presented as a solution for injection (pre‑filled pen) for subcutaneous use. It treats growth hormone deficiency in children and adults and related growth‑related disorders.

GNH USA supplies Norditropin Nordiflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norditropin Nordiflex is a recombinant human growth hormone used to address conditions characterized by insufficient endogenous growth hormone activity. - Growth hormone deficiency in children: promotes normal linear growth and improves body composition. - Turner syndrome: supports height gain during puberty. - Prader‑Willi syndrome: enhances growth velocity and body composition. - Chronic renal insufficiency: helps improve growth in pediatric patients. - Short stature associated with idiopathic GH deficiency: stimulates growth and development. - Adult growth hormone deficiency: improves metabolic profile and quality of life.

Common Side Effects: - Injection site reactions such as redness, swelling, or pain. - Headache. - Joint or muscle aches. - Transient edema or fluid retention.

Serious or Rare Side Effects: - Intracranial hypertension presenting with headache and visual changes. - Slipped epiphysis (growth plate injury) in growing children. - Severe allergic reactions including anaphylaxis. - Abnormal glucose metabolism leading to hyperglycemia or diabetes onset.

Norditropin Nordiflex requires careful monitoring due to its systemic effects. - Monitor glucose levels: patients with diabetes may need dose adjustments. - Assess for intracranial hypertension: watch for persistent headaches or visual disturbances. - Evaluate growth plates: regular radiographs in children to detect slipped epiphysis. - Screen for malignancies: avoid in patients with active cancer. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norditropin Nordiflex may interact with several medications affecting glucose metabolism or hormone pathways. Major Interactions (Avoid): - Concurrent high‑dose insulin or oral hypoglycemics: increased risk of hypoglycemia. - Other growth hormone products: additive effects leading to excess IGF‑1.

Moderate Interactions (Monitor Closely): - Glucocorticoids: may blunt growth‑promoting effects. - Estrogen therapy: can alter IGF‑1 levels and require dose adjustments. - Thyroid hormone replacement: monitor thyroid function tests. - CYP450 enzyme inducers or inhibitors: may affect somatropin clearance.